Table 4.
Cost-effectiveness comparison of PDS treatment strategy versus NACT treatment strategy
| Treatment strategy and cancer stage | Cost | Incremental cost | Effectiveness | Incremental effectiveness | Incremental C/E |
|---|---|---|---|---|---|
| Stage IIIC ovarian cancer | |||||
| NACT | $30,016 | 1.69 QALYs | |||
| PDS | $31,945 | $1,929 | 1.79 QALYs | 0.1 QALYs | $19,359 |
| Stage IV ovarian cancer | |||||
| NACT | $27,338 | 1.66 QALYs | |||
| PDS | $31,869 | $4,531 | 1.69 QALYs | 0.03 QALYs | $130,083 |
Note: Currency is 2010 US$.
Abbreviations: C/E, cost-effectiveness ratio; NACT, neoadjuvant chemotherapy; PDS, primary debulking surgery; QALYs, quality-adjusted life-years.